Plant MedicineEmerging Evidence

Ibogaine

Also known as: Iboga, Tabernanthe iboga

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central West Africa. The Bwiti tradition of Gabon has used iboga in spiritual initiation ceremonies for centuries. Ibogaine is unique among psychedelics for its remarkable abi...

Applications

6

Clinical Trials

3

Evidence Tier

emerging

Duration

8-12 hours acute effects, with subtle aftereffects lasting 24-72 hours

Overview

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central West Africa. The Bwiti tradition of Gabon has used iboga in spiritual initiation ceremonies for centuries. Ibogaine is unique among psychedelics for its remarkable ability to interrupt addiction, particularly to opioids, with a single treatment often eliminating acute withdrawal symptoms for weeks and reducing cravings for months. The mechanism involves resetting multiple neurotransmitter systems, including dopamine, serotonin, and opioid receptors, while promoting neuroplasticity and allowing psychological processing of addiction's root causes. A typical ibogaine experience lasts 8-12 hours and involves a waking dream state with intense introspection, life review, and often vivid visions addressing the psychological origins of addiction. Studies show up to 88% reduction in PTSD symptoms post-treatment. However, ibogaine carries significant cardiac risks, including QT interval prolongation and potential fatal arrhythmias, necessitating rigorous medical screening and monitoring. Treatment centers in Mexico (Tijuana, Cancun, Playa del Carmen) and Portugal provide medically supervised protocols with cardiac monitoring, pre-treatment screening, and integration support. Texas approved $50 million in 2025 for clinical trials investigating ibogaine for addiction and brain trauma, signaling growing legitimacy.

Traditional Use

Used for centuries in Bwiti spiritual tradition of Gabon and Cameroon for initiation rites, healing ceremonies, and communion with ancestors. Considered sacred medicine providing spiritual insight and physical healing.

Therapeutic Applications

Opioid addiction (heroin, prescription opioids)Alcohol use disorderStimulant addiction (methamphetamine, cocaine)PTSD and traumaDepression and anxietyTraumatic brain injury (emerging research)

Clinical Trials

Texas Ibogaine Research Initiative

Approved 2025 - Not Yet Recruiting
PhasePhase 1/2
InstitutionTexas State Funding ($50M)

Ibogaine for Traumatic Brain Injury

Data Analysis Phase
PhaseObservational
InstitutionStanford University

Ibogaine for Opioid Dependence

Historical Data Collection
PhasePhase 2
InstitutionMAPS

Dosing Guide

Therapeutic Dose

15-25 mg/kg body weight (typically 500-1200mg total dose, administered once)

* Dosing should be individualized. Always consult with a qualified healthcare practitioner.

Risks & Contraindications

Potential Risks

  • Cardiac arrhythmias and QT interval prolongation (potentially fatal)
  • Seizures in vulnerable individuals
  • Intense nausea and physical discomfort
  • Psychological distress during experience
  • Ataxia and coordination difficulties post-treatment
  • Drug interactions with numerous medications
  • Fatalities reported, primarily from cardiac complications or poly-drug use

Contraindications

  • Cardiovascular disease or family history of sudden cardiac death
  • Long QT syndrome
  • Liver or kidney disease
  • Pregnancy and breastfeeding
  • Concurrent use of most medications (requires supervised withdrawal)
  • Active psychosis
  • Severe malnutrition

Legal Status

United States

Schedule I federally with no approved medical use. Legal in Mexico for treatment purposes.

International

Legal in Mexico, Costa Rica, Brazil, South Africa, Gabon. Unregulated in Portugal. Illegal in most Western countries.

Key Researchers

Deborah Mash (University of Miami)Thomas Kingsley Brown (UC San Diego)Kenneth Alper (NYU)Geoff Noller (UCSD)Eduardo Schenberg (Brazil)

Key Studies

  • 1Noller et al. - Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up (2018)
  • 2Brown et al. - Ibogaine and subjective experience: Transformative states and psychopharmacotherapy in the treatment of opioid use disorder (2019)
  • 3Davis et al. - Effects of ibogaine on acute opioid withdrawal and PTSD in veterans (2020)

Quick Facts

CategoryPlant Medicine
Evidence TierEmerging
Duration8-12 hours acute effects, with subtle aftereffects lasting 24-72 hours
Gabriel Brain Score
78/ 100

Coming Soon on Matter

Access vetted treatment centers, practitioner guidance, and protocol tracking through our Matter platform. Early access launching soon.

Treatment Centers

Beond

Featured

Cancun, Mexico

ClinicMedicalLegal
Practitioner Score94
Visit site →

Tabula Rasa Retreat

Featured

Alentejo, Portugal

ClinicMedicalLegal
Practitioner Score92
Visit site →

Clear Sky Recovery

Cancun, Mexico

ClinicMedicalLegal
Practitioner Score89
Visit site →

Experience Ibogaine

Tijuana, Mexico

ClinicMedicalLegal
Practitioner Score88
Visit site →

Transcend Clinic

Cancun, Mexico

ClinicMedicalLegal
Practitioner Score87
Visit site →

IbogaQuest

Tepoztlan, Mexico

ClinicMedicalLegal
Practitioner Score87
Visit site →

Related Substances

Ayahuasca

Ayahuasca is a traditional Amazonian plant brew combining the Banisteriopsis caapi vine (containing MAO inhibitors) with Psychotria viridis leaves (containing DMT). The MAO inhibitors allow the orally inactive DMT to become psychoactive, creating a profound 4-6 hour visionary experience. Indigenous peoples of the Amazon have used ayahuasca for thousands of years in shamanic healing ceremonies for physical ailments, emotional distress, spiritual guidance, and treating addiction. Modern research shows ayahuasca promotes neuroplasticity through sigma-1 receptor activation at mitochondria-associated membranes, reducing inflammation, oxidative stress, and cellular stress responses. Clinical studies demonstrate rapid antidepressant effects, with single doses reducing HAM-D and MADRS scores significantly for up to 21 days. The brew's beta-carboline alkaloids (harmine, harmaline, tetrahydroharmine) contribute additional anthelmintic, antimicrobial, vasorelaxant, and neuroprotective properties. Ayahuasca shows particular promise for substance dependence, acting on mesolimbic dopaminergic and serotonergic pathways to break addiction cues and attenuate withdrawal symptoms. The experience typically involves purging (vomiting, diarrhea), which is considered part of the healing process. Emerging research suggests potential for neurodegenerative conditions like Parkinson's, Alzheimer's, and ALS.

ModerateLearn more →

Bufo Alvarius (5-MeO-DMT)

Bufo alvarius (now Incilius alvarius), the Sonoran Desert toad, produces venom containing high concentrations of 5-MeO-DMT, one of the most potent psychedelics known. Despite widespread belief in traditional indigenous use, there is no verified evidence of ceremonial toad venom consumption by indigenous peoples. The Yaqui of the Sonoran Desert considered the toad culturally significant in art and stories but explicitly deny historical ingestion of its venom as psychoactive. Archaeological evidence suggests Mesoamerican awareness of psychoactive toads, but not confirmed ceremonial use. Modern "Bufo ceremonies" emerged around 2015 as neo-shamanic practices, often held at retreats in Tulum, Riviera Maya, Sonora, Oaxaca (Mexico), and Peru's Sacred Valley. The dried venom is vaporized and smoked, producing an extremely intense 15-45 minute experience of ego dissolution, unity consciousness, white light, and often profound healing or trauma release. The toad naturally secretes venom from glands when threatened; this is collected, dried, and stored. Rising global demand for Bufo ceremonies has created serious conservation concerns, with wild toad populations under pressure from over-harvesting. Synthetic 5-MeO-DMT offers an identical experience without harming toads and is increasingly preferred by ethical practitioners. The experience is considered one of the most powerful and potentially transformative in psychedelic medicine, but also carries risks of overwhelming psychological intensity.

EmergingLearn more →

San Pedro / Huachuma

San Pedro (Echinopsis pachanoi), known as Huachuma in indigenous traditions, is a mescaline-containing cactus native to the Andes mountains of Peru, Bolivia, Ecuador, and surrounding regions. With over 4,000 years of ceremonial use, it is one of the oldest entheogens in the Americas, predating psilocybin mushroom use. Archaeological evidence from Peru's Chavín culture (1500 BCE) shows stone carvings of shamans holding the cactus. The Inca used San Pedro in ceremonies at Cusco, Machu Picchu, and the Sacred Valley for spiritual communion with deities, purification, divination, healing, and governance counsel. The primary psychoactive compound, mescaline, increases prefrontal cortex activity for emotional regulation and planning while producing heart-opening, empathogenic effects alongside visual enhancements. Traditional curanderos (healers) in Peru and Ecuador use San Pedro tea in blended indigenous-modern medicine for shamanic healing, enhancing perception, awakening intuition, and diagnosing mind-body-spirit imbalances. The experience, lasting 10-14 hours, typically brings euphoria, compassion, empathy, enhanced environmental awareness, and insights into personal problems. Research supports traditional claims of blood pressure reduction, anti-inflammatory effects, and benefits for depression, anxiety, PTSD, and addiction recovery through serotonin and dopamine activation.

TraditionalLearn more →